{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:02:13Z","timestamp":1784538133834,"version":"3.55.0"},"reference-count":52,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The last decade has transformed the conceptual landscape of fatty liver disease in three ways [...]<\/jats:p>","DOI":"10.3390\/life16071197","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:54:13Z","timestamp":1784534053000},"page":"1197","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Health: The Interplay Between NAFLD, MAFLD, MASLD, and Cardiovascular Disease"],"prefix":"10.3390","volume":"16","author":[{"given":"Monika","family":"R\u00f3\u017cycka-Kosmalska","sequence":"first","affiliation":[{"name":"Department of Electrocardiology, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0609-9657","authenticated-orcid":false,"given":"Marcin","family":"Kosmalski","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Morawska, A., Frankowski, R., Grabarczyk, M., Kosmalski, M., and R\u00f3\u017cycka-Kosmalska, M. (2025). Crosstalk Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation: Shared Mechanism, Diagnostic Integration, and Management Implications. Life, 15.","DOI":"10.3390\/life15111713"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Coste, S.-C., Hilda Or\u0103\u0219an, O., Cozma, A., Negrean, V., Alexescu, T.G., Perne, M.G., Ciulei, G., Hangan, A.C., Lucaciu, R.L., and Iancu, M. (2024). Allelic, Genotypic, and Haplotypic Analysis of Cytokine IL17A, IL17F, and Toll-like Receptor TLR4 Gene Polymorphisms in Metabolic-Dysfunction-Associated Steatotic Liver Disease: Insights from an Exploratory Study. Life, 14.","DOI":"10.3390\/life14101327"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mosca, A., Panera, N., Andolina, G., Della Volpe, L., Pastore, A., Braghini, M.R., Monti, L., Francalanci, P., Soglia, G., and Pietrobattista, A. (2026). The Role of Homocysteine in Pediatric MASLD: A Bipotential Biomarker of Cardiovascular Risk and Liver Fibrosis. Life, 16.","DOI":"10.3390\/life16020191"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nguyen, L.N.B., and Vo, T.D. (2025). Comparison of Triglyceride-Glucose Index Indices and Fatty Liver Index in Predicting Metabolic Dysfunction-Associated Fatty Liver Disease: A Cross-Sectional Study Conducted in Vietnam. Life, 15.","DOI":"10.3390\/life15111702"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"R\u00f3\u017cycka-Kosmalska, M., Luzak, B., and Kosmalski, M. (2026). Clinically Inferred Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Association with Atrial Fibrillation Subtypes: A Prospective Clinical and Cardiometabolic Analysis. Life, 16.","DOI":"10.3390\/life16071101"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kwon, Y., Chung, J.A., Choi, Y.J., Lee, Y.M., Choi, S.Y., Yoo, I.H., Kim, T.H., and Jeong, S.J. (2024). Relationship of the Degree of Sarcopenia with the Severity of Nonalcoholic Fatty Liver Disease and Cardiometabolic Risk in Adolescents. Life, 14.","DOI":"10.3390\/life14111457"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"M\u00e9ndez-Garc\u00eda, L.A., Escobedo, G., Baltazar-P\u00e9rez, I., Ocampo-Aguilera, N.A., Arreola-Miranda, J.A., Cid-Soto, M.A., Alfaro-Cruz, A., Gonz\u00e1lez-Ch\u00e1vez, A., Oca\u00f1a-Guzm\u00e1n, A.R., and Solleiro-Villavicencio, H. (2024). Exploring the Th2 Response in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Potential Modulator of the Renin-Angiotensin System (RAS) Pathway in Hypertension Development. Life, 14.","DOI":"10.3390\/life14091080"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Gonz\u00e1lez, \u00c1.A., Mart\u00ednez-Almoyna Rif\u00e1, E., Oliveira, H.P., S\u00e1nchez, C.M., T\u00e1rraga L\u00f3pez, P.J., and Ram\u00edrez-Manent, J.I. (2025). Association Between Sociodemographic Variables, Healthy Habits, and Stress with Risk Scales for Liver Disease Associated with Metabolic Dysfunction. Life, 15.","DOI":"10.3390\/life15010116"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yilmaz, A., Toraman, M.N., Mataraci Karakas, S., Ozden, Z., Pinarbas, E., and Mercantepe, T. (2024). Effect of White Tea on Leptin and Asprosin Levels in Rats Feeding a High-Fat Diet. Life, 14.","DOI":"10.3390\/life14121548"},{"key":"ref_10","first-page":"S32","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"32","author":"Younossi","year":"2024","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/CEOR.S472446","article-title":"Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives","volume":"16","author":"Torre","year":"2024","journal-title":"Clin. Outcomes Res."},{"key":"ref_14","first-page":"A15","article-title":"A systematic review and meta-analysis: Does metabolic dysfunction-associated steatotic liver disease increase the risk of cardiovascular disease above and beyond shared risk factors?","volume":"74","author":"Hung","year":"2025","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","first-page":"e89355","article-title":"Evidence from a Systematic Review of Non-alcoholic Fatty Liver Disease (NAFLD)\/Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD) Fueling Cardiovascular Risk","volume":"17","author":"Bhatt","year":"2025","journal-title":"Cureus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/liv.15939","article-title":"Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence","volume":"44","author":"Ciardullo","year":"2024","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3350\/cmh.2023.0277","article-title":"Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1016\/j.jacc.2026.03.056","article-title":"2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Ndumele","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., and Nikolaou, M. (2025). From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework. Biomolecules, 15.","DOI":"10.3390\/biom15020213"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/jdi.70349","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease and cardiovascular disease: Emerging insights into the liver\u2013heart axis","volume":"17","author":"Lee","year":"2026","journal-title":"J. Diabetes Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.jacc.2025.08.100","article-title":"The Basics of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease for Cardiologists","volume":"86","author":"Khan","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12933-024-02321-z","article-title":"Impaired GK-GKRP interaction rather than direct GK activation worsens lipid profiles and contributes to long-term complications: A Mendelian randomization study","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e43952","DOI":"10.1097\/MD.0000000000043952","article-title":"Association between metabolic dysfunction-associated steatotic liver disease and cardiovascular disease: New perspectives","volume":"104","author":"Zhou","year":"2025","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2025","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Chatha, K.K., Than, N.N., Kassi, E., Kyrou, I., and Randeva, H.S. (2025). Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311275"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4070\/kcj.2025.0212","article-title":"Cardiovascular Implications in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"56","author":"Suresh","year":"2026","journal-title":"Korean Circ. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1080\/00365521.2025.2536585","article-title":"Cardiovascular implications of MASLD: Overview of the evidence","volume":"60","author":"Ismail","year":"2025","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Basta, D., Al Refaei, A., Msinjili, L., Frishman, W.H., and Lebovics, E. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: Shared Mechanisms and Therapeutic Opportunities. Cardiol. Rev., online ahead of print.","DOI":"10.1097\/CRD.0000000000001298"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.3567","article-title":"Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure","volume":"27","author":"Chang","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jacbts.2021.07.010","article-title":"Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure with Preserved Ejection Fraction","volume":"6","author":"Salah","year":"2021","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Yang, Z., Tian, R., Zhang, X.J., Cai, J., She, Z.G., and Li, H. (2023). Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2022.1120085"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12933-024-02572-w","article-title":"Association between triglyceride-glucose related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: A cohort study of UK Biobank","volume":"24","author":"Qiao","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","first-page":"11","article-title":"MASLD-A Gateway for ASCVD: A Call for Early Intervention and Multidisciplinary Care","volume":"73","author":"Manoria","year":"2025","journal-title":"J. Assoc. Physicians India"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.20517\/mtod.2024.34","article-title":"Perspective article: Determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge","volume":"4","author":"Jamalinia","year":"2024","journal-title":"Metab. Target Organ Damage"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"120551","DOI":"10.1016\/j.atherosclerosis.2025.120551","article-title":"Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease","volume":"411","author":"Kyhl","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"114657","DOI":"10.3748\/wjg.v32.i13.114657","article-title":"Outcomes of liver and cardiovascular metabolic diseases among lean vs non-lean individuals with metabolic dysfunction-associated steatotic liver disease","volume":"32","author":"Mapouka","year":"2026","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lebovics, N., Heering, G., Frishman, W.H., and Lebovics, E. (2025). Lean MASLD and Cardiovascular Disease: A Review. Cardiol. Rev., online ahead of print.","DOI":"10.1097\/CRD.0000000000000893"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jgh.70194","article-title":"Lean MASH: A High-Risk Subtype With Significant Cardiometabolic Burden","volume":"41","author":"Fouad","year":"2026","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Liang, J., Liang, Y., Chen, L., Cai, M., Li, S., He, L., Xu, Y., Tan, Y., Li, L., and Wu, X. (2025). Cardiovascular-kidney-metabolic progression associated with major adverse liver outcomes: Mediating roles of plasma metabolites. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1675899"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Li, T., Guo, S., and Song, J. (2026). Association of cardiovascular-kidney-metabolic syndrome stages with MASLD prevalence and liver fibrosis severity: Evidence from traditional and machine learning approaches. Eur. J. Med. Res., epub ahead of print.","DOI":"10.1186\/s40001-026-04037-0"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1489-P","DOI":"10.2337\/db25-1489-P","article-title":"Associations between the Cardiovascular-Kidney-Metabolic Syndrome and Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in U.S. and Chinese Populations","volume":"74","author":"Wan","year":"2025","journal-title":"Diabetes"},{"key":"ref_43","first-page":"01557","article-title":"Real-world evidence in metabolic dysfunction-associated steatotic liver disease: Insights, challenges, and future directions","volume":"62","author":"Huang","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"103411","DOI":"10.1016\/j.jceh.2025.103411","article-title":"Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: Facts and Hopes","volume":"16","author":"Adinolfi","year":"2026","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in Adults: A Review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_48","first-page":"A15","article-title":"Phase 3 ESSENCE trial evaluating semaglutide in metabolic dysfunction-associated steatohepatitis: Part 1 results and secondary analysis","volume":"74","author":"Newsome","year":"2025","journal-title":"Gut"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17512433.2025.2573785","article-title":"Semaglutide for the treatment of MASH: Reaching into the ESSENCE of cardio-metabolic health?","volume":"18","author":"Mademlis","year":"2025","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_51","first-page":"165","article-title":"Editorial: An Important Step Towards Mastering Metabolic Dysfunction-Associated Steatohepatitis-Targeted Therapy in Diabetes","volume":"63","author":"Chang","year":"2025","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Machado, M.V. (2023). MASLD treatment-a shift in the paradigm is imminent. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1316284"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1197\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:06:04Z","timestamp":1784534764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["life16071197"],"URL":"https:\/\/doi.org\/10.3390\/life16071197","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}